ClinicalTrials.gg
RecruitingNCT07732283FAST-ECGUpdated Sep 11, 2026

4-electrode ECG (DigitalCardio®) vs Standard 10-electrode ECG: Evaluating Ease of Use and Recording Quality

An interventional study of standard 10-electrode ECG acquisition and 4-electrode DigitalCardio acquisition in 4-electrode Tablet-based Electrocardiogram (ECG) System, Electrical Activity of the Heart and Atrial or Ventricular Arrhythmias, sponsored by Clinique Bizet. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Clinique Bizet · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Myocardial Ischemia with a site in France — 10 open to participants now, 14 under way, none of them phase 3. Myocardial Ischemia · France.

Planned enrollment
36th of 43
50 · median 313
Started
2026
with 1 other
No phase
20 of 63
6 open now
Primary completion
2026-12
later than 7 of 13 live
Registered
63rd of 63
by date

Among the 63 studies in Myocardial Ischemia with a site in France, this one is the 36th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 63rd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

10 of the 63 studies in Myocardial Ischemia with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Myocardial Ischemia with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the time required to record a complete Electrocardiogram (ECG) trace using the DigitalCardio (CardioSecur®) tablet device versus a standard 12-lead ECG device in eligible patients.

The main questions it aims to answer are:

Is there a difference in diagnostic recording time (in minutes) between the DigitalCardio tablet and a standard ECG machine? How do the two devices compare in terms of trace quality (including QRS duration, QT interval, frontal axis measurements, and missing/erroneous leads)? How satisfied are healthcare professionals with the CardioSecur® device?

Researchers will compare Group A (standard 10-electrode ECG followed by 4-electrode ECG) to Group B (4-electrode ECG followed by standard 10-electrode ECG) in a 1:1 randomized crossover design to evaluate recording efficiency and trace quality.

Participants will:

Complete an initial screening visit with the principal investigator to review eligibility criteria and sign the informed consent form.

Be randomly assigned (1:1 ratio) to either Group A or Group B. Undergo both ECG recording methods sequentially (a standard 10-electrode ECG and a 4-electrode ECG using the DigitalCardio tablet), while researchers measure the total time elapsed from electrode placement to obtaining a complete trace.

Read the detailed description

This study is a randomized, crossover clinical trial designed to compare the efficiency, trace quality, and user satisfaction of a novel 4-electrode tablet-based Electrocardiogram (ECG) system (DigitalCardio / CardioSecur®) against a standard 12-lead (10-electrode) ECG device.

Background and Rationale

An electrocardiogram (ECG) is a fundamental diagnostic tool used to record the electrical activity of the heart. Conventional 12-lead ECGs require placing 10 individual electrodes on a patient's limbs and chest while the patient is lying down. While highly detailed, electrode placement and device setup can be time-consuming in clinical workflows. The DigitalCardio tablet system utilizes a simplified 4-electrode setup designed to streamline data acquisition without compromising diagnostic accuracy.

Study Design and Procedures

After an initial screening process led by the principal investigator, eligible participants receive detailed study information and provide written informed consent. Enrolled participants are then randomly assigned in a 1:1 ratio to one of two sequence groups to control for order effects:

*Group A:Undergoes standard 10-electrode ECG acquisition first, followed immediately by 4-electrode DigitalCardio acquisition.

Group B: Undergoes 4-electrode DigitalCardio acquisition first, followed immediately by standard 10-electrode ECG acquisition.

To maintain consistency, both ECG recordings for a given participant are performed by the same healthcare operator within a minimal time interval.

Key Measurements

  1. Diagnostic Time:Research staff record the exact time elapsed (in minutes) from the initiation of electrode placement to the successful capture of a complete ECG trace for both devices.
  2. Trace Quality and Concordance:Printed and anonymized ECG traces are submitted to independent evaluators. Evaluators independently assess trace quality based on standardized criteria, comparing automated measurements (frontal axis, median QRS duration, and QT interval) and counting any missing or erroneous leads.
  3. Healthcare Professional Satisfaction:Participating healthcare professionals complete a structured questionnaire evaluating user satisfaction and usability of the CardioSecur® device in routine practice.
03

Conditions studied

  • 4-electrode Tablet-based Electrocardiogram (ECG) System
  • Electrical Activity of the Heart
  • Atrial or Ventricular Arrhythmias
  • Intracardiac Conduction Abnormalities
  • QT Interval Prolongation
  • Myocardial Ischemia
  • Ventricular Hypertrophy
  • Tandard 12-lead (10-electrode) ECG Device

Browse trials for

Keywords

  • 4-electrode tablet-based Electrocardiogram (ECG) system
  • standard 12-lead (10-electrode) ECG device
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Hospitalized Cardiology Patients:

  • Age minimum 18 years
  • Hospitalized for an acute or chronic cardiac condition (e.g., heart failure, acute coronary syndrome, arrhythmia, valvular heart disease, etc.)
  • Ability to give
  • Hemodynamic stability permitting the performance of an without clinical risk

Cardiology Outpatients:

  • Age minimum of 18 years
  • Follow-up for a known cardiac condition or suspected cardiovascular disease
  • No to performing an ECG
  • Informed consent obtained

Exclusion criteria

Exclusion Criteria:

  • Minor patient (\< 18 years of age)
  • Adult subject under legal protection, under temporary guardianship, curatorship, or tutelage
  • Patient refusing to participate in the study
  • Presence of an implantable cardiac device (e.g., pacemaker, defibrillator) that may interfere with measurements
  • Severe skin condition preventing the placement of electrodes
  • Physical or cognitive inability to follow the study protocol
  • Current pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    standard 10-electrode ECG

    Undergoes standard 10-electrode ECG acquisition first

    Device: standard 10-electrode ECG acquisition · Device: 4-electrode DigitalCardio acquisition

  • Active comparator
    4-electrode DigitalCardio

    Undergoes 4-electrode DigitalCardio

    Device: standard 10-electrode ECG acquisition · Device: 4-electrode DigitalCardio acquisition

Interventions

  • Devicestandard 10-electrode ECG acquisition

    Patient undergoes standard 10-electrode ECG acquisition. Then anonymized ECG traces is printed are submitted to independent evaluators. Evaluators independently assess trace quality based on standardized criteria, comparing automated measurements (frontal axis, median QRS duration, and QT interval) and counting any missing or erroneous leads. Followed immediately by 4-electrode DigitalCardio acquisition.

  • Device4-electrode DigitalCardio acquisition

    Patient undergoes 4-electrode DigitalCardio acquisition acquisition. Then anonymized ECG traces is printed are submitted to independent evaluators. Evaluators independently assess trace quality based on standardized criteria, comparing automated measurements (frontal axis, median QRS duration, and QT interval) and counting any missing or erroneous leads. Followed immediately by standard 10-electrode ECG acquisition.

06

What researchers measure

Primary outcomes

  1. Comparison of Procedure Time Between 4-Electrode DigitalCardio® ECG and Standard 12-Lead ECG

    Time elapsed from the initiation of electrode placement to the obtaining of a complete ECG trace for both the 4-electrode DigitalCardio® system and the standard 12-lead ECG device. Unit of Measure: Minutes

    Time frame: 1 day

Secondary outcomes

  1. Comparative Quality Assessment of ECG Traces

    Proportion of paired recordings in which an independent cardiologist prefers the 4-electrode DigitalCardio® trace compared to the standard 12-lead ECG trace, based on visual evaluation of signal clarity and the presence of artifacts/interference. Unit of Measure: Percentage of paired recordings

    Time frame: 1 day

  2. Intraclass Correlation Coefficient (ICC) for Quantitative ECG Parameters

    Degree of agreement for quantitative clinical parameters (e.g., QRS duration, QT interval, frontal axis measurements) automatically provided by both the 4-electrode DigitalCardio® system and the standard 12-lead ECG device. Unit of Measure: Intraclass Correlation Coefficient (ICC) (ranging from 0 to 1, where higher values indicate better agreement)

    Time frame: 1 day

  3. Diagnostic Concordance for Cardiac Pathology

    Agreement in detecting the presence or absence of cardiac pathology using the 4-electrode DigitalCardio® system compared to the standard 12-lead ECG (gold standard). Unit of Measure: Percentage of concordant diagnostic evaluations

    Time frame: 1 day

  4. Healthcare Professional Satisfaction Score

    Overall user satisfaction regarding the ease of use of the DigitalCardio® tablet device, evaluated by participating healthcare professionals using a structured Likert scale. The score ranges from 1 (strongly disagree / highly unsatisfied) to 5 (strongly agree / highly satisfied), where higher scores indicate a better outcome (higher satisfaction). Unit of Measure: Score on a scale

    Time frame: 1 days

  5. Incidence of Device-Related Technical Incidents for 4-electrode DigitalCardio® system

    Total number of technical malfunctions, failures, or operational incidents reported for 4-electrode DigitalCardio® system devices during procedures. And how the issu is been managed. Unit of Measure: Number of technical incidents

    Time frame: 1 day

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24. No abstract available. PubMed 22922414 ↗
  • Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29. No abstract available. PubMed 26320110 ↗
  • Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393. No abstract available. PubMed 28886621 ↗
  • Nelwan SP, Kors JA, Crater SW, Meij SH, van Dam TB, Simoons ML, Krucoff MW. Simultaneous comparison of 3 derived 12-lead electrocardiograms with standard electrocardiogram at rest and during percutaneous coronary occlusion. J Electrocardiol. 2008 May-Jun;41(3):230-7. doi: 10.1016/j.jelectrocard.2008.01.011. PubMed 18433614 ↗
  • Welinder AE, Wagner GS, Horacek BM, Martin TN, Maynard C, Pahlm O. EASI-Derived vs standard 12-lead electrocardiogram for Selvester QRS score estimations of chronic myocardial infarct size, using cardiac magnetic resonance imaging as gold standard. J Electrocardiol. 2009 Mar-Apr;42(2):145-51. doi: 10.1016/j.jelectrocard.2008.10.010. Epub 2008 Dec 18. PubMed 19100565 ↗
  • Horacek BM, Warren JW, Penney CJ, MacLeod RS, Title LM, Gardner MJ, Feldman CL. Optimal electrocardiographic leads for detecting acute myocardial ischemia. J Electrocardiol. 2001;34 Suppl:97-111. doi: 10.1054/jelc.2001.28844. PubMed 11781943 ↗
  • Martinez JP, Laguna P, Olmos S, Pahlm O, Pettersson J, Sornmo L. Assessment of QT-measurement accuracy using the 12-lead electrocardiogram derived from EASI leads. J Electrocardiol. 2007 Apr;40(2):172-9. doi: 10.1016/j.jelectrocard.2006.08.089. Epub 2006 Oct 6. PubMed 17027840 ↗
  • Denes P. The importance of derived 12-lead electrocardiography in the interpretation of arrhythmias detected by Holter recording. Am Heart J. 1992 Oct;124(4):905-11. doi: 10.1016/0002-8703(92)90971-w. PubMed 1382387 ↗
  • Drew BJ, Koops RR, Adams MG, Dower GE. Derived 12-lead ECG. Comparison with the standard ECG during myocardial ischemia and its potential application for continuous ST-segment monitoring. J Electrocardiol. 1994;27 Suppl:249-55. doi: 10.1016/s0022-0736(94)80100-2. No abstract available. PubMed 7884370 ↗
  • Drew BJ, Ide B. Diagnosing ischemia from the bedside monitor. Prog Cardiovasc Nurs. 1996 Winter;11(1):45-6. No abstract available. PubMed 8657711 ↗
  • Schächinger, Volker, Bartosz Przybyla, Pilotstudie zur Detektion von Myokardischämie mit einer auf EASI Standard basierten 3D-Vektor-Eketrokardiographie (CardioSecur), Klinikum Fulda, unpublished
  • Okada, Kozo, Comparison of App-based 22-lead electrocardiogram with standard 12-lead electrocardiogram for the diagnosis of acute coronary syndromes, Yokohama City University Medical Center, unpublished
  • Johnson H, Duarte N, Ryding D, Perry D, McNally S, Stuart AG, Williams CA, Pieles G. Assessment of a Novel, 22-lead Mobile Electrocardiogram in Elite, Adolescent Footballers. Int J Sports Med. 2022 Mar;43(3):245-253. doi: 10.1055/a-1537-9757. Epub 2021 Aug 13. PubMed 34388845 ↗
  • Spaich S, Kern H, Zelniker TA, Stiepak J, Gabel M, Popp E, Katus HA, Preusch MR. Feasibility of CardioSecur(R), a Mobile 4-Electrode/22-Lead ECG Device, in the Prehospital Emergency Setting. Front Cardiovasc Med. 2020 Oct 9;7:551796. doi: 10.3389/fcvm.2020.551796. eCollection 2020. PubMed 33195450 ↗
  • De Bie J, Martignani C, Massaro G, Diemberger I. Performance of seven ECG interpretation programs in identifying arrhythmia and acute cardiovascular syndrome. J Electrocardiol. 2020 Jan-Feb;58:143-149. doi: 10.1016/j.jelectrocard.2019.11.043. Epub 2019 Nov 30. PubMed 31884310 ↗
  • C.M. Yong, V. Froelicher, G. Wagner L'électrocardiogramme à la croisée des chemins Circulation., 128 (1) (2013), p. 79-82 Voir dans ScopusGoogle Scholar
  • D.M.F. Palhares, M.S. Marcolino, T.M.M. Santos, J.L.P. da ilva, P.R. Gomes, L.B. Ribeiro, et al.Limites normales de l'électrocardiogramme dérivées d'une grande base de données de patients brésiliens en soins primaires BMC Cardiovasc Disord, 17 (1) (2017), p. 152 Voir dans ScopusGoogle Scholar
  • P.W. Macfarlane, S.M. Lloyd, D. Singh, S. Hamde, E. Clark, B. Devine, et al. Limites normales de l'électrocardiogramme chez les Indiens J Electrocardiol, 48 (4) (2015), p. 652 à 668 Voir le PDF Voir l'articleVoir dans ScopusGoogle Scholar
  • Katibi I, Clark EN, Devine B, Lloyd SM, Macfarlane PW. Normal limits of the electrocardiogram in Nigerians. J Electrocardiol. 2013 Jul-Aug;46(4):289-95. doi: 10.1016/j.jelectrocard.2013.04.002. Epub 2013 May 20. PubMed 23702151 ↗
  • T.F. Yang, P.W. Macfarlane Nouvelles limites normales dépendantes du sexe de l'électrocardiogramme moyen du signal Br Heart J, 72 (2) (1994), pp. 197-200 Voir sur l'éditeurRéf. croiséeVoir dans ScopusGoogle Scholar
  • P.W. Macfarlane, T.D.V. Lawrie L'électrocardiogramme normal et le vectorcardiogramme P.W. Macfarlane, Av Oosterom, O. Pahlm, P. Kligfield, M. Janse, J. Camm (Eds.), Comprehensive Electrocardiology (2. 2 éd.), Springer, Londres (2010), pp. 483-546)
  • Wagner GS, Macfarlane P, Wellens H, Josephson M, Gorgels A, Mirvis DM, Pahlm O, Surawicz B, Kligfield P, Childers R, Gettes LS, Bailey JJ, Deal BJ, Gorgels A, Hancock EW, Kors JA, Mason JW, Okin P, Rautaharju PM, van Herpen G; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009 Mar 17;53(11):1003-11. doi: 10.1016/j.jacc.2008.12.016. No abstract available. PubMed 19281933 ↗
  • Bayés de Luna, A., Wagner, G. S., Birnbaum, Y., Nikus, K., Fiol, M., Gorgels, A., Pahlm, O., & Sclarovsky, S. (2008). A new terminology for left ventricular walls and location of myocardial infarcts that present Q wave based on the standard of the American Heart Association Committee on Electrocardiography and the Cardiac Mapping Committee of the International Society for Holter and Noninvasive Electrocardiology. Journal of Electrocardiology, 41(4), 342-347. DOI: 10.1016/j.jelectrocard.2008.02.008
  • Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med. 2003 Mar 6;348(10):933-40. doi: 10.1056/NEJMra022700. No abstract available. PubMed 12621138 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 3 months is below that.

Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Sep 4, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07732283
Lead sponsor
Clinique Bizet
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Sep 4, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Bouchra BENKESSOU Chef de projet Recherche Clinique
Contact
b.benkessou@hexagone-sante-paris.fr
+33 7 64 48 60 16

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion